Vemurafenib
- PDF / 130,776 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 7 Downloads / 129 Views
1
S
Cutaneous toxicities in an elderly patient: case report A 79-year-old woman developed cutaneous toxicities of phototoxicity, verrucae and squamous cell carcinoma (SCC) while receiving vemurafenib. The woman was diagnosed with two primary melanomas in 2008. She underwent wide local excision of the primary lesions. A sentinel lymph node biopsy of the left axilla showed metastatic melanoma, and she underwent complete left axillary dissection. In 2011, imaging showed a mass in the duodenum and regional adenopathy, while pathology showed metastatic melanoma of the small bowel. Her tumour harboured the serine-threonine protein kinase B-RAF (BRAF) mutation, and she started vemurafenib [dosage and route not stated]. In the month after starting the drug, she went on a cross-country trip, and developed significant phototoxicity although she used sunscreen. As the phototoxicity improved, she developed a diffuse scaly eruption and cutaneous nodules. Biopsy of the two lesions revealed verruca vulgaris and a welldifferentiated squamous cell carcinoma [outcome not stated]. Author comment: "Our patient poignantly demonstrates three of the most common cutaneous side effects of BRAF inhibition in patients treated [with vemurafenib] for metastatic melanoma: phototoxicity, development of verrucae, and formation of cutaneous SCCs and [keratoacanothomas]." Shea SM, et al. Cutaneous side effects of vemurafenib: a case report and discussion. Wiener Medizinische Wochenschrift 163: 376-379, No. 15-16, Aug 2013. Available from: URL: http://dx.doi.org/10.1007/s10354-013-0217-1 803095327 USA
0114-9954/13/1477-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
Reactions 9 Nov 2013 No. 1477
Data Loading...
